"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

行业表现 - 多家临床阶段生物技术公司在盘后交易中出现强劲上涨势头 受即将发布的试验数据和研发管线更新推动 [1] MBX Biosciences Inc (MBX) - 股价在盘后交易中飙升33% 从10美元涨至13.77美元 涨幅达37.70% [2] - 公司宣布将于9月22日周一公布Canvuparatide治疗慢性甲状旁腺功能减退症的2期试验顶线结果 [2] - 常规交易时段收盘下跌0.70% 从10.07美元跌至10美元 [3] Structure Therapeutics Inc (GPCR) - 盘后股价上涨11.37%至26.26美元 常规时段收盘价为23.58美元 [3] - 当日成交量超过100万股 略高于92.9万股的日均成交量 [3] - 主要候选药物aleniglipron (GSBR-1290)正在进行两项2b期试验ACCESS和ACCESS II 针对肥胖及相关代谢疾病 [4] - 公司计划启动ACCG-2671的1期试验 这是一种口服淀粉素受体激动剂 [4] - 现金储备约7.865亿美元 预计可支持研发管线至2027年 [4] Cartesian Therapeutics Inc (RNAC) - 盘后股价上涨5.51%至9.96美元 常规时段收盘价为9.45美元 [5] - 当日成交量达214,825股 远高于约66,000股的日均成交量 [5] - Descartes-08治疗系统性红斑狼疮的2期开放标签试验初步数据预计2025年下半年公布 [6] - 截至2025年6月30日 现金及限制性现金为1.621亿美元 预计可支持运营至2027年中 [7] Rapport Therapeutics Inc (RAPP) - 盘后股价上涨3.60%至27.31美元 常规时段收盘价为26.36美元 [8] - 当日成交量超过150万股 是日均成交量639,563股的两倍多 [8] - 主要候选药物RAP-219针对局灶性发作癫痫 本月公布的2a期试验显示显著减少癫痫发作和良好耐受性 [9] - 预计2026年启动RAP-219的3期试验 [10] Rezolute Inc (RZLT) - 盘后股价上涨3.77%至7.99美元 常规时段收盘价为7.70美元 [11] - 当日创下52周新高8.81美元 成交量超过475万股 远高于115万股的日均成交量 [11] - 先天性高胰岛素血症3期sunRIZE试验顶线数据预计2025年12月公布 [12] - 与FDA就肿瘤性高胰岛素血症3期试验简化设计达成一致 减少研究规模并取消安慰剂对照组 [12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-39683 REZOLUTE, INC. (Exact Name of Company as Specified in its Charter) | Nevada | | 27-3440894 | | --- | --- | --- | | ( ...

Exhibit 99.1 · In August 2025, the Company achieved alignment with FDA on a significantly streamlined clinical development path for its ongoing Phase 3 study (upLIFT) of ersodetug for the treatment tumor HI. o The truncated study will include as few as 16 participants and will be limited to the single-arm open-label portion of the upLIFT study, removing the need to conduct a double-blind randomized placebo-controlled trial. o Enrollment is underway and topline results are expected in the second half of 2026 ...

REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025. “We have made substantial progress this year across our two indications for ersodetug in both congenital and tumor hyperinsulinism,” said Nevan Charles Elam, Chief Executi ...

公司高管交易 - 首席财务官Evans Daron于2025年12月9日以每股5.04美元价格购入10,549股公司普通股 [1] - 此次交易使其总持股量增至131,900股 [1] - 该交易通过Form 4文件向美国证券交易委员会申报 [1] 核心产品研发进展 - 公司主要候选药物Ersodetug已获得FDA突破性疗法认定 可加速审批流程 [2] - 该药物针对罕见代谢疾病治疗领域 [2] - 目前处于III期临床试验阶段 具备成为重磅药物的潜力 [2] 财务表现与估值指标 - 公司市盈率为负值-7.41 但仍处于预收入阶段 [3] - 市销率达到11,579.47 反映市场对其增长前景的高度认可 [3] - 企业价值与销售额比率高达11,358.42 显示估值溢价明显 [4] - 企业价值与经营现金流比率为负值-10.04 表明财务方面存在挑战 [4] 资本结构与流动性 - 债务权益比率仅为0.0215 显示公司几乎不依赖债务融资 [4] - 流动比率达8.43 表明公司短期资产完全能够覆盖短期负债 [5] - 财务稳定性结合Ersodetug药物潜力 为公司提供显著增长空间 [5]

核心药物进展 - 主要候选药物Ersodetug获得FDA突破性疗法认定 进入快速审批通道[1] - 该药物针对难治性高胰岛素血症 目前正在进行两项III期临床试验并已开始患者招募[2] - 药物作用机制使其有潜力治疗该疾病的所有形式[2] 财务预测与市场潜力 - 公司预测前两个目标市场的销售额峰值可能超过10亿美元[3] - 预计2026年开始产生收入 随后8-10年将保持连续增长[3] - 2028年前将保持超高速增长 之后5-7年放缓至可持续的两位数增长[4] - 预计2027年实现盈利 之后数年利润将以接近三位数的高双位数速度增长[4] 分析师观点与股价表现 - 5位分析师一致给予买入评级 目标价平均为11.67美元 预示55%上涨空间[5] - H.C. Wainwright的Douglas Tsao重申买入评级 目标价14美元为区间高点 较共识目标还有20%上行空间[6] - 2025年股价已上涨超过200% 技术指标MACD显示看涨信号[13] 机构持仓与市场活动 - 机构持股比例超过80% 且每季度都呈现看涨活动[7] - 机构买入量在2025年逐步攀升至创纪录高位[7] - 空头兴趣也在上升 8月空头比例创历史新高超过10%[10] 财务状况与风险因素 - 公司目前尚未产生收入 但拥有足够资本维持约6个季度的运营[11] - 公司无企业债务 但面临股权稀释风险 截至第三季度末流通股数同比增长36%[12] - 股价在8美元附近遇到阻力 可能限制近期涨幅[13]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

会议介绍 - 摩根士丹利医疗保健团队Kelly McCarthy主持与Rezolute公司CEO Nevan Elam的会议 [1] - Rezolute公司CEO Nevan Elam参与摩根士丹利医疗保健会议 [1] - 会议重点讨论Rezolute公司发展情况 [1]

Rezolute (NasdaqCM:RZLT) FY Conference September 09, 2025 12:20 PM ET Speaker0I'm very happy to be here with the CEO of Resolute, Nevan Elam. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and really excited to have you at our conference. I know you got a great schedule of meetings, and we're excited to talk a little bit more about the Resolute story. So before we get into it, I'm gonna read this quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure ...